Skip to content
DraconiticResearch
Search Sources API
181,686 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BYCureus

Prolonged Active SARS-CoV-2 Infection in a Patient With Chronic Lymphocytic Leukemia on Venetoclax.

  • Brian Laverentz1
  • Nhu Do1
  • Leslie A Jette-Kelly2
  • Christina Schofield3
  1. 1Internal Medicine, Madigan Army Medical Center, Tacoma, USA.
  2. 2Pulmonology and Critical Care, Madigan Army Medical Center, Tacoma, USA.
  3. 3Infectious Diseases, Madigan Army Medical Center, Tacoma, USA.
Read full textPDFDOICite

Abstract

We report a case of prolonged active SARS-CoV-2 infection in a patient with chronic lymphocytic leukemia (CLL) receiving venetoclax. The patient demonstrated persistent symptoms over a span of 105 days and repeatedly positive SARS-CoV-2 polymerase chain reaction (PCR) testing. The case highlights the diagnostic and therapeutic challenges in immunocompromised hosts, including limited guidance and drug availability. Management required multiple antiviral regimens and consideration of alternative therapies. This case underscores the need for further research that can inform more robust guidelines and therapeutic strategies in this vulnerable population.

Related

  1. T cell–driven venetoclax resistance in chronic lymphocytic leukemia: in vivo preclinical activity of opaganib
    Valeria Judith Sarapura Martínez, Paula Soledad Pérez, Anita Ng +16
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textHuman geneticsCrossrefEurope PMCEurope PMCPMC
  2. Prolonged treatment-free remission after venetoclax in combination with a hypomethylating agent in acute myeloid leukemia with inv(16).
    Morgan L Shannon, Jared Wallace, Amy Kuo +1
    Annals of hematologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  3. Infection Profiles Under Venetoclax‐Based Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
    Guilin Ren, Guangyu Zhou, Hao Zhou +8
    Cancer medicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. SAFETY AND ANTITUMOR ACTIVITY OF NEMTABRUTINIB PLUS VENETOCLAX IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: PART 1 OF THE PHASE 3 BELLWAVE-010 STUDY
    Paolo GHIA, Mauricio CHANDIA CABAS, Vernon Johan LOUW +13
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textHuman geneticsDOAJ
  5. A Rare Case of Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia in an Elderly Patient: A Case Report
    Mostafa Kamandi, Mohammad Mahdi Alvandi Fard
    Clinical case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{laverentz2026prolonged,
  title = {{Prolonged Active SARS-CoV-2 Infection in a Patient With Chronic Lymphocytic Leukemia on Venetoclax.}},
  author = {Brian Laverentz and Nhu Do and Leslie A Jette-Kelly and Christina Schofield},
  journal = {Cureus},
  year = {2026},
  month = sep,
  doi = {10.7759/cureus.116542},
  url = {https://europepmc.org/article/MED/42903358},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Prolonged Active SARS-CoV-2 Infection in a Patient With Chronic Lymphocytic Leukemia on Venetoclax.
AU  - Brian Laverentz
AU  - Nhu Do
AU  - Leslie A Jette-Kelly
AU  - Christina Schofield
PY  - 2026
DA  - 2026/09/19
JO  - Cureus
DO  - 10.7759/cureus.116542
UR  - https://europepmc.org/article/MED/42903358
AB  - We report a case of prolonged active SARS-CoV-2 infection in a patient with chronic lymphocytic leukemia (CLL) receiving venetoclax. The patient demonstrated persistent symptoms over a span of 105 days and repeatedly positive SARS-CoV-2 polymerase chain reaction (PCR) testing. The case highlights the diagnostic and therapeutic challenges in immunocompromised hosts, including limited guidance and drug availability. Management required multiple antiviral regimens and consideration of alternative therapies. This case underscores the need for further research that can inform more robust guidelines and therapeutic strategies in this vulnerable population.
SN  - 2168-8184
ER  -